Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension

Journal of Cardiology

Volumn 61, Issue 6, 2013, Pages 417-422

  Taniguchi, Tatsunori ^a   Ohtani, Tomohito ^a   Mizote, Isamu ^a   Kanzaki, Machiko ^a   Ichibori, Yasuhiro ^a   Minamiguchi, Hitoshi ^a   Asano, Yoshihiro ^a   Sakata, Yasushi ^a   Komuro, Issei ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta adrenergic receptor blocker; Drug administration; Heart failure

Indexed keywords

BISOPROLOL; CARVEDILOL;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPOTENSION; LABORATORY TEST; MALE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; BISOPROLOL; CARBAZOLES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PROPANOLAMINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878992102     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.01.009     Document Type: Article

References (27)

1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., Jaarsma T., Køber L., Lip G.Y., Maggioni A.P., Parkhomenko A., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
2. Butler J., Young J.B., Abraham W.T., Bourge R.C., Adams K.F., Clare R., O'Connor C. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006, 47:2462-2469. ESCAPE Investigators.
3. Fonarow G.C., Abraham W.T., Albert N.M., Stough W.G., Gheorghiade M., Greenberg B.H., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008, 52:190-199. OPTIMIZE-HF Investigators and Coordinators.
4. Jondeau G., Neuder Y., Eicher J.C., Jourdain P., Fauveau E., Galinier M., Jegou A., Bauer F., Trochu J.N., Bouzamondo A., Tanguy M.L., Lechat P. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009, 30:2186-2192. B-CONVINCED Investigators.
5. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996, 334:1349-1355.
6. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Staiger C., Holcslaw T.L., Amann-Zalan I., DeMets D.L. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
7. Hori M., Sasayama S., Kitabatake A., Toyo-oka T., Handa S., Yokoyama M., Matsuzaki M., Takeshita A., Origasa H., Matsui K., Hosoda S. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004, 147:324-330. MUCHA Investigators.
8. Metra M., Nodari S., Dei Cas L. Beta-blockade in heart failure: selective versus non-selective agents. Am J Cardiovasc Drugs 2001, 1:3-14.
9. A randomized trial of beta-blockade in heart failure. Circulation 1994, 90:1765-1773. The Cardiac Insufficiency Bisoprolol Study (CIBIS): CIBIS Investigators and Committees.
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
11. Willenheimer R., van Veldhuisen D.J., Silke B., Erdmann E., Follath F., Krum H., Ponikowski P., Skene A., van de Ven L., Verkenne P., Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005, 112:2426-2435. CIBIS III Investigators.
12. Düngen H.D., Apostolovic S., Inkrot S., Tahirovic E., Töpper A., Mehrhof F., Prettin C., Putnikovic B., Neskovic A.N., Krotin M., Sakac D., Lainscak M., Edelmann F., Wachter R., Rau T., et al. CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure, Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011, 13:670-680.
13. Takeda Y., Sakata Y., Mano T., Ohtani T., Kamimura D., Tamaki S., Omori Y., Tsukamoto Y., Aizawa Y., Komuro I., Yamamoto K. Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 2011, 13:664-669.
14. Nul D., Zambrano C., Diaz A., Ferrante D., Varini S., Soifer S., Grancelli H., Doval H. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina, Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy - a report from the GESICA registry. Cardiovasc Drugs Ther 2005, 19:125-134.
15. Lepor H., Alpha1 adrenoceptor subtype: clinical or theoretical benefit? Br J Urol 1995, 76(Suppl. 1):57-61.
16. Lepor H., Jones K., Williford W. The mechanism of adverse events associated with terazosin: an analysis of the veteran's affairs cooperative study. J Urol 2000, 163:1134-1137.
17. Di Lenarda A., Remme W.J., Charlesworth A., Cleland J.G., Lutiger B., Metra M., Komajda M., Torp-Pedersen C., Scherhag A., Swedberg K., Poole-Wilson P.A. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 2005, 7:640-649. COMET investors.
18. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996, 94:2807-2816.
19. Simon T., Mary-Krause M., Funck-Brentano C., Lechat P., Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Eur Heart J 2003, 24:552-559.
20. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., Ganiats T.G., Konstam M.A., Mancini D.M., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee, 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 119:1977-2016.
21. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
22. Hoshikawa E., Matsumura Y., Kubo T., Okawa M., Yamasaki N., Kitaoka H., Furuno T., Takata J., Doi Y.L. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011, 107:1065-1070.
23. Sato Y., Fujiwara H., Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012, 59:1-7.
24. Shiba N., Shimokawa H. Chronic kidney disease and heart failure - bidirectional link and common therapeutic goal. J Cardiol 2011, 57:8-17.
25. Konishi M., Haraguchi G., Kimura S., Inagaki H., Kawabata M., Hachiya H., Hirao K., Isobe M. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ J 2010, 74:1127-1134.
26. Vardeny O., Wu D.H., Desai A., Rossignol P., Zannad F., Pitt B., Solomon S.D. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012, 60:2082-2089. RALES Investigators.
27. Rouleau J.L., Roecker E.B., Tendera M., Mohacsi P., Krum H., Katus H.A., Fowler M.B., Coats A.J., Castaigne A., Scherhag A., Holcslaw T.L., Packer M. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004, 43:1423-1429. Carvedilol Prospective Randomized Cumulative Survival Study Group.